

Docket No.

111828-00109

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Siegler

SERIAL NO: 10/644,797

GAU: TBD

FILED: August 21, 2003

EXAMINER: TBD

FOR: SERUM MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AS MARKER FOR PROSTATE
CANCER



INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a copy of applicant's pending application(s) or issued patent(s) which may be related to the present application. These documents are listed on form PTO-1449, also attached.

A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in any counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

This Information Disclosure Statement is being filed within three months of the filing date of the subject patent application.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits.

PETITION


Applicant(s) hereby request consideration of the attached information. A check is attached in the amount of the Petition fee required under 37 CFR §1.17(i)(1).

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 23-2185. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

BLANK ROME LLP



Charles R. Wolfe
Attorney of Record
Registration No. 28,680

600 NEW HAMPSHIRE AVENUE, N.W.
WASHINGTON, DC 20037
TEL (202) 944-3000
FAX (202) 572-8398



27557

PATENT TRADEMARK OFFICE

Date:

5/3/04

08/01

O I P E J C I T A
MAY 03 2004

Sheet 1 of 1

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY DOCKET NO. & TRADEMARK OFFICE 111828-00109	SERIAL NO. 10/644,797		
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT K. M. Siegler			
				FILING DATE August 21, 2003	GROUP TBD		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	6,043,044	Mar. 28, 2000	Hudson et al.	435	7.23	
	AB	5,250,297	Oct. 5, 1993	Grauer et al.	424	88	
	AC	5,614,372	Mar. 25, 1997	Lilja et al.	435	7.23	
	AD	5,654,161	Aug. 5, 1997	Tewari	435	7.23	
	AE	6,268,151	Jul. 31, 2001	Murray et al.	435	6	
	AF	6,420,188	Jul. 16, 2002	Bucala et al.	436	500	
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						
	AR						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	Vandenbroeck et al. 2003. Cytokine gene polymorphism in multifactorial diseases: gateways to novel targets for immunotherapy? Trends in Pharmacol. Sci. 24(6):284-289.					
	AX	Meyer-Siegler et al. 2002. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer. 94(5):1449-1456.					
	AY						
	AZ						
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							